<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17811" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Arginase Deficiency</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Morales</surname>
            <given-names>Andres</given-names>
          </name>
          <aff>Stanford University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sticco</surname>
            <given-names>Kristin L.</given-names>
          </name>
          <aff>Stony Brook University Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andres Morales declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kristin Sticco declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17811.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Argininemia is an autosomal recessive disorder causing hyperammonemia secondary to arginine accumulation. It is a disorder first noticed in children with growth reduction, slowing cognition, and milestone development. Often diagnosed at birth through newborn screening (NBS), affected newborns are found to have elevated levels (up to 4 times) of arginine. Its management is similar to other classic urea cycle disorders, although with mild or absent hyperammonemia. If hyperammonemia is present, it responds adequately to ammonia-reducing interventions. Chronic treatment consists of protein restriction along with nitrogen-scavenging medications. This activity describes the evaluation and management of argininemia and explains the role of the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the etiology of patients with argininemia.</p></list-item><list-item><p>Identify the presentation of patients with argininemia.</p></list-item><list-item><p>Summarize the use of ammonia reduction strategies in managing patients with argininemia.</p></list-item><list-item><p>Explain the importance of collaboration and communication among interprofessional team members to enhance care delivery for patients affected by argininemia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17811&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17811">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17811.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Arginase deficiency (argininemia) is an autosomal recessive metabolic disorder characterized by hyperammonemia secondary to arginine accumulation. Ammonia levels can vary according to the patient&#x02019;s current age and status, presenting initially with slow growth, followed by developmental delay and cognitive problems. When improperly treated, it may lead to regression.&#x000a0;</p>
        <p>Often diagnosed at birth through newborn screening (NBS), affected newborns are found&#x000a0;to have elevated levels (up to 4 times) of arginine. Its management is similar to other classic urea cycle disorders, although with mild or absent hyperammonemia. If hyperammonemia is present, it responds adequately to ammonia-reducing interventions. Chronic treatment consists of protein restriction along with nitrogen-scavenging medications.<xref ref-type="bibr" rid="article-17811.r1">[1]</xref></p>
      </sec>
      <sec id="article-17811.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Biallelic pathogenic or likely pathogenic variants in <italic toggle="yes">ARG1</italic> lead to an unstable arginase enzyme, a protein found primarily in hepatic cytosol and responsible for the&#x000a0;final step of the urea cycle.&#x000a0;<xref ref-type="bibr" rid="article-17811.r2">[2]</xref>&#x000a0;This&#x000a0;results in the hydrolysis of arginine to urea and ornithine.</p>
        <p>Another gene, <italic toggle="yes">ARG2,&#x000a0;</italic>responsible for arginase activity, can be found mainly in the mitochondria of extrahepatic tissues, the kidney being a significantly affected location with lower levels in the brain and gastrointestinal tract. However, it is not translated in enough quantities to compensate for the primary <italic toggle="yes">ARG1</italic> defect.<xref ref-type="bibr" rid="article-17811.r3">[3]</xref></p>
      </sec>
      <sec id="article-17811.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Arginase deficiency is the most uncommon urea cycle disorder. The estimated incidence ranges from 0.5 to 1 per 1,000,000.<xref ref-type="bibr" rid="article-17811.r4">[4]</xref>&#x000a0;No particular genotype-phenotype correlations have been postulated to date, meaning there is no accurate method to indicate a particularly affected population.<xref ref-type="bibr" rid="article-17811.r1">[1]</xref><xref ref-type="bibr" rid="article-17811.r5">[5]</xref></p>
      </sec>
      <sec id="article-17811.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Arginase, commonly found in the liver, erythrocytes, and salivary glands, catalyzes the fifth and last reaction of the urea cycle, hydrolyzing L-arginine into ornithine and urea.&#x000a0;</p>
        <p>Its deficiency or absence causes accumulation of arginine, reversibly translating into ammonia overproduction at different levels and expressions after 1 to 3 years of life, although a few cases have been reported in early infancy.&#x000a0;</p>
        <p>Orotic acid accumulation can be found, given that reduction of ornithine impairs ornithine transcarbamylase activity, creating a backup or overflow of carbamyl phosphate, which is subsequently shunted to the pyrimidine synthetic path.<xref ref-type="bibr" rid="article-17811.r6">[6]</xref><xref ref-type="bibr" rid="article-17811.r5">[5]</xref></p>
      </sec>
      <sec id="article-17811.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Brain lesions (cortical atrophy, ischemic changes, and edema) have been found on neuroimaging and histopathology of patients with arginase deficiency, similar to those (patients) affected by hypoxic-ischemic events.<xref ref-type="bibr" rid="article-17811.r7">[7]</xref></p>
        <p>Late manifestations of the liver include fibrosis, cirrhosis, and hepatocellular carcinoma.<xref ref-type="bibr" rid="article-17811.r8">[8]</xref></p>
      </sec>
      <sec id="article-17811.s7" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>The substantial toxic effect of ammonia accumulation causes brain damage through cerebral edema. Affected regions include the parietal, occipital, and frontal lobes.<xref ref-type="bibr" rid="article-17811.r8">[8]</xref>&#x000a0;Another proposed mechanism suggests ammonia (in a minor role) along with guanidino compounds (polyamines, nitrous oxide, agmatine) through the enzyme arginine-glycine amidinotransferase could be the reason for neurotoxicity and spasticity.<xref ref-type="bibr" rid="article-17811.r9">[9]</xref></p>
      </sec>
      <sec id="article-17811.s8" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Arginase deficiency (argininemia) rarely presents in the newborn/infant period. Hyperammonemia may still be present, but it is not life-endangering. After 1 to 3 years of life, patients develop intermittent episodic hyperammonemia, which can be induced by catabolic states (infections), high dietary protein intake, or medications (valproate). This status can only be recognized when the patient presents&#x000a0;with an acute, precipitating incident.<xref ref-type="bibr" rid="article-17811.r10">[10]</xref></p>
        <p>While developing, patients progressively present a reduction of linear growth (100%) and spastic diplegia (the most obvious sign of the condition)&#x000a0;while cognitive development stagnates or regresses.<xref ref-type="bibr" rid="article-17811.r2">[2]</xref> Particular long-term cognitive manifestations evidenced in recent studies include intellectual disability, attention deficit hyperactivity disorder (ADHD), aggressive behaviors, pervasive&#x000a0;development disorder, memory recollection, and fine motor skills impairment. The last two&#x000a0;are remarkable in the adult population. Extraneurological manifestations can present, but prevalence is rare. These included mild to severe liver dysfunction and bone involvement.<xref ref-type="bibr" rid="article-17811.r2">[2]</xref></p>
        <p>If no treatment is provided, patients will develop severe complications of the abnormalities stated above. Objective neurologic findings discovered through&#x000a0;brain&#x000a0;imaging studies&#x000a0;consist of seizures, microcephaly, and cortical atrophy.<xref ref-type="bibr" rid="article-17811.r11">[11]</xref><xref ref-type="bibr" rid="article-17811.r8">[8]</xref></p>
      </sec>
      <sec id="article-17811.s9" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Newborn screening programs around the nation can successfully detect high arginine levels. However, it is not universal yet; around 12 states do not include it in their analysis. Therefore, in individuals with no such opportunity, a high index of suspicion should rise if they present with regression of development milestones.<xref ref-type="bibr" rid="article-17811.r10">[10]</xref></p>
        <p>Initial steps to be performed after a positive newborn screen are plasma ammonia levels, plasma amino acids, and urine organic acids (with a focus on orotic acid).&#x000a0;</p>
        <p>Elevated arginine levels (which can rise 4-fold) and ammonia levels (if present, above 200 micrograms/dL), along with increased orotic acid, are suggestive. Subsequent arginase enzyme analysis on red blood cells (less than 1%) or molecular analysis of <italic toggle="yes">ARG1</italic>&#x000a0;confirm the diagnosis; however, the latter is considered the first confirmatory step due to the difficulty of performing enzyme analysis.<xref ref-type="bibr" rid="article-17811.r4">[4]</xref></p>
        <p>This initial stage is critical, as there are other types of urea cycle disorders that benefit from arginine administration to reduce ammonia levels by indirectly increasing citrulline levels; at the same time, it attaches ammonia molecules for excretion.&#x000a0;</p>
      </sec>
      <sec id="article-17811.s10" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>For acute states, hyperammonemia usually requires no more than conservative treatment, i.e., intravenous (IV) fluids. The use of nitrogen scavengers like sodium phenylacetate or sodium benzoate for severe or moderate cases, along with restriction of protein intake and the introduction of non-protein calorie sources like fats and carbohydrates. When using carbohydrates with intravenous fluids, use dextrose 10% and appropriate electrolytes (sodium and/or potassium) for age. Avoid overhydration, as cerebral edema can occur. Abstinence from protein should not last more than 24&#x000a0;to 48 hours, as further catabolism can occur.&#x000a0;In some cases, particularly in the presence of severe hyperammonemia refractory to medical interventions, clinicians could consider&#x000a0;reduction by dialysis, either through CRRT (continuous renal replacement therapy) or hemodialysis. Dialysis should be stopped once ammonia levels reach 250 micrograms/dL or lower. Should seizures present, use phenobarbital or carbamazepine. Valproate is contraindicated since it induces hyperammonemia.<xref ref-type="bibr" rid="article-17811.r10">[10]</xref></p>
        <p>For maintenance, protein restriction should be in the minimal protein intake range to help with basic functions and development. With half of the dietary protein free of arginine, a total absence of this amino acid cannot be accepted, given its essential role for T cell and endothelial function.&#x000a0;Ideal protein intake in infants ranges from 1 to 1.5 gm/kg. As the child grows, the restriction can be tolerated at lower levels. Daily administration of nitrogen scavengers on maintenance dosing is sodium phenylbutyrate 350 to 600 mg/kg per day.</p>
        <p>Other authors advocate for ornithine supplementation, which could replenish hepatic ornithine and prevent hyperammonemia&#x000a0;while also inhibiting the formation of neurotoxic guanidino compounds.<xref ref-type="bibr" rid="article-17811.r12">[12]</xref><xref ref-type="bibr" rid="article-17811.r13">[13]</xref>&#x000a0;</p>
        <p>Liver transplantation can be considered the ultimate treatment to reduce recurrent hyperammonemia.</p>
        <p>There should be monthly visits during infancy, with progressively increased intervals between visits as the patient grows: monitor liver function, arginine levels, spasticity, and development.</p>
        <p>Preference should be given to medications that bypass liver metabolism over other medications. Examples are ibuprofen over acetaminophen or another antiepileptic over valproate.</p>
        <p>Research has been implemented to provide a better response or an ultimate cure for this pathology. Various trials have used approaches like enzyme replacement therapy, adeno-associated viral vectors, CRISPR-associated protein nine genome editing, and induced pluripotent stem cells. Some have shown a successful response to their target goal. However, these results have not all been translated into a clinical setting due to their early stages.<xref ref-type="bibr" rid="article-17811.r6">[6]</xref><xref ref-type="bibr" rid="article-17811.r4">[4]</xref></p>
      </sec>
      <sec id="article-17811.s11" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Despite elevated levels of arginine in comparison to other amino acids that may even be encountered as normal on newborn screening or amino acid profile, suggest&#x000a0;a strong diagnosis of arginase deficiency. Other urea cycle disorders should be considered, particularly in the event of hyperammonemia without a strong amino acid profile.<xref ref-type="bibr" rid="article-17811.r6">[6]</xref><xref ref-type="bibr" rid="article-17811.r4">[4]</xref></p>
      </sec>
      <sec id="article-17811.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for most patients remains a mystery. The disorder is rare, and follow-up has been poor. However, most patients develop moderate to severe neurological damage, leading to poor quality of life if completely affected.&#x000a0;</p>
      </sec>
      <sec id="article-17811.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Untreated children may&#x000a0;present with seizures, spasticity, short stature, and intellectual disability. Most infants affected with this condition are now identified at birth through newborn screening, although this is not the norm everywhere.</p>
      </sec>
      <sec id="article-17811.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Parents of affected patients should understand that their child will need&#x000a0;periodic blood testing to determine ammonia and arginine blood levels and to ensure that liver function is not impaired. Excessive ammonia or arginine levels should&#x000a0;receive prompt treatment.</p>
        <p>Genetic counseling is recommended for individuals affected by this disease&#x000a0;and their family members.</p>
      </sec>
      <sec id="article-17811.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Given the broad phenotype and variable presentation, an initial, thorough investigation of proband can later expand to siblings or other relatives should they present with similar symptomatology.<xref ref-type="bibr" rid="article-17811.r14">[14]</xref>&#x000a0;</p>
        <p>For prenatal testing, gene sequencing should be the first diagnostic step, like chorionic villus sampling, and amniocytes lack arginase become unsuitable procedures.<xref ref-type="bibr" rid="article-17811.r15">[15]</xref></p>
      </sec>
      <sec id="article-17811.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Arginase deficiency (argininemia) is an autosomal recessive metabolic disorder characterized by hyperammonemia secondary to arginine accumulation. The disorder is rare and is best managed by an interprofessional team that includes a pediatrician, geneticist, endocrinologist, and dietitian. The disorder is sometimes identified during the screening of the newborn. The ammonia levels can vary according to the&#x000a0;patient&#x02019;s age and status, presenting initially with a reduction of growth and moving to milestone development and cognition. Sometimes when not treated, the disorder leads to regression.&#x000a0;</p>
        <p>Often diagnosed at birth through newborn screening (NBS), affected newborns are found&#x000a0;to have elevated levels (up to 4 times) of arginine. Its management corresponds classically as another urea cycle defect, with mild or absent hyperammonemia and, if present, responds adequately to reductive ammonia actions. Chronic treatment consists of protein restriction along with nitrogen-scavenging medications.<xref ref-type="bibr" rid="article-17811.r1">[1]</xref> Genetics nurses and nurse practitioners are involved in patient care, education, and follow-up. The pharmacist should educate the caregiver on the need for compliance with medication and assist in the acute treatment of neurologic events, reporting any concerns they encounter to the prescribing clinician. All care team members must maintain open communication channels and keep accurate patient records, so everyone involved in patient care has the same updated information to make decisions. This interprofessional model will help drive optimal patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-17811.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17811&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17811">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/arginase-deficiency/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17811">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17811/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17811">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17811.s18">
        <title>References</title>
        <ref id="article-17811.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morris</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Arginases and arginine deficiency syndromes.</article-title>
            <source>Curr Opin Clin Nutr Metab Care</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>64</fpage>
            <page-range>64-70</page-range>
            <pub-id pub-id-type="pmid">22037011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17811.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sin</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schulze</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Funk</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Arginase-1 deficiency.</article-title>
            <source>J Mol Med (Berl)</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>93</volume>
            <issue>12</issue>
            <fpage>1287</fpage>
            <page-range>1287-96</page-range>
            <pub-id pub-id-type="pmid">26467175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17811.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waisbren</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Gropman</surname>
                <given-names>AL</given-names>
              </name>
              <collab>Members of the&#x000a0;Urea Cycle Disorders Consortium (UCDC)</collab>
              <name>
                <surname>Batshaw</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Improving long term outcomes in urea cycle disorders-report from the Urea Cycle Disorders Consortium.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>573</fpage>
            <page-range>573-84</page-range>
            <pub-id pub-id-type="pmid">27215558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17811.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Therrell</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Currier</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lapidus</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Grimm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cederbaum</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Newborn screening for hyperargininemia due to arginase 1 deficiency.</article-title>
            <source>Mol Genet Metab</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>121</volume>
            <issue>4</issue>
            <fpage>308</fpage>
            <page-range>308-313</page-range>
            <pub-id pub-id-type="pmid">28659245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17811.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iyer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jenkinson</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Vockley</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Kern</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Grody</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Cederbaum</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The human arginases and arginase deficiency.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>1998</year>
            <volume>21 Suppl 1</volume>
            <fpage>86</fpage>
            <page-range>86-100</page-range>
            <pub-id pub-id-type="pmid">9686347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17811.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yahyaoui</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Blasco-Alonso</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Benito</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Garc&#x000ed;a</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ald&#x000e1;miz-Echevarr&#x000ed;a</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz-Hern&#x000e1;ndez</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Vega</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Cerd&#x000e1;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Mart&#x000ed;n</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>A new metabolic disorder in human cationic amino acid transporter-2 that mimics arginase 1 deficiency in newborn screening.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>2019</year>
            <month>May</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>407</fpage>
            <page-range>407-413</page-range>
            <pub-id pub-id-type="pmid">30671984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17811.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000fc;ng&#x000f6;r</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Akinci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Firat</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Tabel</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Alkan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Neuroimaging findings in hyperargininemia.</article-title>
            <source>J Neuroimaging</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>457</fpage>
            <page-range>457-62</page-range>
            <pub-id pub-id-type="pmid">18321250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17811.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Khera</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>A Case of Hyperargininaemia Presenting at Unusually Low Age.</article-title>
            <source>J Clin Diagn Res</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>11</volume>
            <issue>7</issue>
            <fpage>BD01</fpage>
            <page-range>BD01-BD03</page-range>
            <pub-id pub-id-type="pmid">28892883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17811.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deignan</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Marescau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Livesay</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>De Deyn</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Cederbaum</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Grody</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Increased plasma and tissue guanidino compounds in a mouse model of hyperargininemia.</article-title>
            <source>Mol Genet Metab</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>93</volume>
            <issue>2</issue>
            <fpage>172</fpage>
            <page-range>172-8</page-range>
            <pub-id pub-id-type="pmid">17997338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17811.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cederbaum</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Grody</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Kern</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Arginases I and II: do their functions overlap?</article-title>
            <source>Mol Genet Metab</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>81 Suppl 1</volume>
            <fpage>S38</fpage>
            <page-range>S38-44</page-range>
            <pub-id pub-id-type="pmid">15050972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17811.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asrani</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Subramanian</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Arginase I mRNA therapy - a novel approach to rescue arginase 1 enzyme deficiency.</article-title>
            <source>RNA Biol</source>
            <year>2018</year>
            <volume>15</volume>
            <issue>7</issue>
            <fpage>914</fpage>
            <page-range>914-922</page-range>
            <pub-id pub-id-type="pmid">29923457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17811.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain-Ghai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nagamani</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Blaser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Siriwardena</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Feigenbaum</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Arginase I deficiency: severe infantile presentation with hyperammonemia: more common than reported?</article-title>
            <source>Mol Genet Metab</source>
            <year>2011</year>
            <season>Sep-Oct</season>
            <volume>104</volume>
            <issue>1-2</issue>
            <fpage>107</fpage>
            <page-range>107-11</page-range>
            <pub-id pub-id-type="pmid">21802329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17811.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amayreh</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Treatment of arginase deficiency revisited: guanidinoacetate as a therapeutic target and biomarker for therapeutic monitoring.</article-title>
            <source>Dev Med Child Neurol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>56</volume>
            <issue>10</issue>
            <fpage>1021</fpage>
            <page-range>1021-4</page-range>
            <pub-id pub-id-type="pmid">24814679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17811.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Morales</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sticco</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <chapter-title>Arginase Deficiency</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">29493987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17811.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diez-Fernandez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>R&#x000fc;fenacht</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gemperle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fingerhut</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>H&#x000e4;berle</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Mutations and common variants in the human arginase 1 (ARG1) gene: Impact on patients, diagnostics, and protein structure considerations.</article-title>
            <source>Hum Mutat</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>39</volume>
            <issue>8</issue>
            <fpage>1029</fpage>
            <page-range>1029-1050</page-range>
            <pub-id pub-id-type="pmid">29726057</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
